90PostersPO-044FISHING NUP98 INVOLVEMENT IN HEMATOLOGICALMALIGNANCIES WITH 11P15 KARYOTYPIC CHANGESLa Starza R,* Crescenzi B,* Rosati R,* Gorello P,*Schoch C, # Romoli S,* Testoni N,° Santoro A, +Martelli MF,* Mecucci C**Ematologia, Policlinico Monteluce, Università degliStudi di Perugia, Perugia, Italy, # Labor fur Leukaemie-diag<strong>no</strong>stik,Medizinische Klinik III, Munchen,Germany, ° Ematologia, Istituto Serag<strong>no</strong>li, Universitadi Bologna, Italy + Ematologia, Università di Palermo,Palermo, ItalyNUP98 gene is one of the so-called promiscuousgenes as at least 15 partners of translocations arek<strong>no</strong>wn. It is involved in both de <strong>no</strong>vo and secondaryhematological malignancies such as acute myeloid(AML) and lymphoid leukemias (ALL), Ph-positivechronic myeloid leukemia (CML), T-cell <strong>no</strong>n-Hodgkin’slymphomas. In order to pick up NUP98 rearrangements,we set up a FISH approach with DNA clonesselected for NUP98 and in some cases for the putativepartner genes. We collected twelve cases with aNUP98 translocation and the following diag<strong>no</strong>sis: 2T-ALL with t(4;11)(q12;p15); one refractory anemiawith excess of blasts and a cryptic ins(5;11) (q35;p15p14); three AML-M2 and one Ph + CML witht(7;11)(p15;p15); one AML with t(8;11) (p11.2,p15);one secondary AML-M2 with t(10;11) (q22;p15); twoAML-M2 with t(11;12) (p15;q13); and one AML-M4with inv(11)(p15q22). NUP98 was investigated byFISH with clone RP5-1173K1 spanning exons 10 to 20of the gene. Additional experiments were performedwith clones selected for the following partner chromosome/genes:5q35/NSD1 (CTC-549A4), 7p15/HOXA (RP1-170K19, 170O19, 18M17, 113H19,167F23), 8p11.2/NSD3 (RP11-350N15), 12q13/HOXC(RP11-877M13, 578A18, 219N9). The RP5-1173K1clone detected NUP98 rearrangements in all casesresulting in three hybridization signals on <strong>no</strong>rmal 11,on der(11), and on the partner chromosome. Thisapproach allowed us to identify a crypticNUP98/NSD1 fusion resulting from an insertion ofthe 5NUP98 within the 5q35/NSD1 locus. Clonesselected to study k<strong>no</strong>wn partner chromosomes/geneswere validated: insertion of 5;NUP98 into NSD1 wasdemonstrated with double colour experiment usingRP5-1173K1 and CTC-549A4; 3/4 patients witht(7;11) showed the same breakpoint at 7p15 withinclone RP1-170O19; the t(8;11) can be easily detect bycombining RP5-1173K1 and RP11-350N15 in doublecolour since two fusion signals are present on bothder(8) and der(11). In one case of t(11;12) the12q13/HOXC breakpoint was narrowed within RP11-877M13.FISH is a useful tool to perform wide screeningof NUP98 involvement. We validated a number ofclones to study specific NUP98 translocations. Thesetools will be helpful to unravel the incidence and theclinical impact of NUP98 rearrangements.Funding: This work was partially supported by CNR-MIUR, and FIRB.PO-045TELOMERASE ACTIVITY IN ACUTE PROMYELOCYTIC LEUKEMIA(AML-M3): A STUDY ON 35 PATIENTSCalatroni S, 1 Bernasconi P, 1 Klersy C, 2 Rocca B, 1Boni M, 1 Caviglia<strong>no</strong> PM, 1 Giardini I, 1 , Zappatore R, 1Caresana M, 1 Quarna J, 1 Lazzari<strong>no</strong> M 11Università degli Studi di Pavia, Divisione di Ematologia,Policlinico San Matteo IRCCS; 2 DirezioneScientifica, Unità di Epidemiologia Clinica e Biometria,IRCCS Policlinico San Matteo, Pavia, ItalyTelomerase is formed by two subunits TERC, theRNA template needed for telomere synthesis, andhTERT, the rate-limiting catalytic protein subunit.Telomerase plays a crucial role in preserving thelength of telomeres, nucleoprotein structures positionedat the end of eukaryotic chromosomes. Physiologicalerosion of telomeres occurs after subsequentrounds of cell division and prevents tumour formationby limiting cell life span. However, when some tumorsuppressor genes (namely TP53 or RB-1) are targetedby mutations, the cell enters a period of geneticinstability and may acquire additional geneticdefects. Some of these cells die by apoptosis, whileothers survive due to constitutive activation oftelomerase. Therefore, it is <strong>no</strong>t surprising that hTERTactivity has been found amplified in many haematologicaldisorders. The aims of the present study wereto evaluate whether hTERT activity was correlatedwith peculiar clinical parameters, with the presenceof FLT3 internal tandem duplication (ITD) and withrelapse in 35 LAM-M3 patients. The thirty-fivepatients entered in the present study were analysedat the onset of the disease and during the follow-up.hTERT relative quantification was obtained througha real-time polymerase chain reaction whichemployed SybrGreen I, a DNA-binding fluorescentdye. Serial dilution of total RNA from the K562 cellline were used to set the standard curve for real-timequantification. hTERT expression was <strong>no</strong>rmalized toABL and calibrated on K562.In order to make statisticalanalysis hTERT values were dichotomised so thatpatients could be subdivided in those with high andlow hTERT activity. Comparisons of hTERT values duringthe follow-up were made by using a regressionmodel for repeated measurements and correlationswith clinical parameters and relapse were obtained byapplying the Spearman test and Cox regression. Eighteenpatients were males and seventeen females;haematologica vol. <strong>89</strong>[suppl. n. 6]:september <strong>2004</strong>
VIII Congress of the Italian Society of Experimental Hematology, Pavia, September 14-16, <strong>2004</strong>91their median age was 42 years (range 8-71). All thepatients except five, who died during the inductionchemotherapy, achieved a complete remission (CR)after a median time of 42 days (range 32-68). Themedian follow-up time is <strong>no</strong>w 29 months (range 0-92). Twenty-three patients are in CR after a medianfollow-up time of 29 months (range 3-92), while sevenhave relapsed after a median follow-up time of 20months (range 9-42). A second CR was achieved in allthese last patients except in one who presented highhTERT transcript levels along with FLT3 ITD. Thispatient died just before performing an allogeneicbone marrow transplantation (Allo-BMT). Two otherpatients in second CR underwent an allo-BMT. One ofthem with high hTERT transcript levels and FLT3 ITDexperienced a third relapse but succeeded in reachinga new CR after additional intensive chemotherapy.The other patient with low levels of hTERT transcriptlevel and without FLT3 ITD is in an un-maintainedCR 24 months from the transplant. A highwhite blood cell (WBC) count either at clinical diag<strong>no</strong>sisor at relapse was the only clinical parameterwhich was significantly correlated with high hTERTtranscript levels (p=0.037). Mean hTERT transcriptlevel were 6.4 (range:0.7-9.9) for patients with highWBC and 4.9 (range: 0.3-14.7) for those with <strong>no</strong>rmalWBC at the onset of the disease. High hTERT valueswere observed in five out of the six FLT3 ITD positivepatients. Considering all the patients hTERT levelspresented ups and downs during the follow-up. Weevaluated whether hTERT values determined eitherat clinical diag<strong>no</strong>sis or at one hundred-eighty daysfrom it could predict relapse. We found that relapserate was 4.7% (95% confidence intervals, CI=0.6-33.0) for patients who at the onset of the diseasehad low hTERT transcript levels versus 15.9% (95%CI=6.2-42) for patients who had high levels. Theselast patients showed a hazard risk of relapse of 4.3%(95% CI=0.48-39) (p=0.14). These same significantcorrelations were found for hTERT values determinedat one hundred-eighty days from the onset of thedisease. At this time relapse rate was 6.8% (95% CI:0.9-48) for patients with low hTERT values versus21.7% (95% CI: 7.0-67) for those with high levels.These last patients showed a hazard risk of relapse of3.5% (95% CI: 0.37-34) (p=0.23). In conclusion i)highhTERT values are significantly correlated with highWBC count; ii) are more often seen in patients withFLT3 ITD; iii) are predictive of relapse independentlyof whether they are determined at diag<strong>no</strong>sis or atone hundred-eighty days from it.PO-046EPIGENETIC EVENTS INVOLVED IN THE TRANSCRIPTIONALSILENCING OF RA-TARGET GENES IN ACUTE MYELOIDLEUKEMIAFazi F,* # Gelmetti V,* # Pascale S,* # Travaglini L,* #Diverio D,° Lo Coco F, § Pelicci PG, ? Nervi C* #*Dipartimento di Istologia ed Embriologia Medica,°Biotec<strong>no</strong>logie Cellulari ed Ematologia, Università“La Sapienza” e § Biopatologia Università “Tor Vergata”,Rome; # Parco Scientifico Biomedico di Rome SanRaffaele, Rome; ? Istituto Europeo di Oncologia,Milan, ItalyAberrant recruitment of HDAC activities favoringhypermethylation of target promoters underlies thepathogenetic action of AML-associated fusion proteinAML1/ETO. Recent studies indicate that HDACare present in complexes containing DNA-methyltransferase(DNMT's) and methyl-CpG bindingdomain proteins (MBDs) to remodel chromatin andlink deacetylation-mediated gene silencing to DNAmethylation. Our previous observation indicated thata transcriptional repression of RA-signaling pathwayunderlies the pathogenesis of <strong>no</strong>n APL AML-M2 andAML-M4.Using Southern blot analysis of ge<strong>no</strong>micDNA and by methylation- specific PCR (MSP) wefound that the RARβ2 promoter region containingthe β-RARE and transcription start site is methylatedin 7/9 AML-M2, 9/10 AML-M4 and in 6/8AML1/ETO positive samples. The region located in the5'portion of the exon 1 of RARβ2 is methylated in 9/9AML-M2, 8/10 AML-M4 and 8/8 AML1/ETO positivesamples. Neither of these RARβ2 regions is foundmethylated in CD34 + <strong>no</strong>rmal hemopoietic precursors.RARβ expression is detectable in <strong>no</strong>rmal CD34 + cellsbut <strong>no</strong>t in any of the 24 AML cases analyzed. Weanalyzed whether the expression of AML1-ETO intohematopoietic progenitors induces repression of RAsignalingpathway by affecting the methylation statusat RA-target genes. By using AML patients blastsand cell lines carrying an endoge<strong>no</strong>us AML1/ETO(Kasumi and SKNO) or stably transfected with an HAtagged AML1/ETO (U937-AE) as cell model systemour preliminary results indicates that: i) AML1/ETO ispresent on AML1 (p14arf) and RA (RAR?2) targetgene promoters complexed with DNMT and MBDactivities as shown by chromatin immu<strong>no</strong>precipitation(ChIP) assay; ii) in the absence or in the presenceof RA, the expression of AML1-ETO down-regulatesin a dose-dependent manner the transactivation of atransiently transfected 5Kb RARβ promoter; iii) theexpression of AML1-ETO induces hypermethylatio<strong>no</strong>f the promoter/exon1 region of RARβ2 gene; iv)both histone deacetylase and DNA methyltransferaseinhibitors relieve the transcriptional repression of RAtarget genes and restore the differentiation responsehaematologica vol. <strong>89</strong>[suppl. n. 6]:september <strong>2004</strong>
- Page 1 and 2:
haematologicahJournal of Hematology
- Page 3:
haematologicaeditorial boardeditor-
- Page 6:
supplement 6, September 2004Table o
- Page 9 and 10:
VIII Congress of the Italian Societ
- Page 11 and 12:
VIII Congress of the Italian Societ
- Page 13 and 14:
VIII Congress of the Italian Societ
- Page 15 and 16:
VIII Congress of the Italian Societ
- Page 18 and 19:
12Main ProgramAcknowledgments: this
- Page 20 and 21:
14Main Programhaematologica vol. 89
- Page 22 and 23:
16Oral Communicationsexpression. TR
- Page 24 and 25:
18Oral CommunicationsBEST-06NK CELL
- Page 26 and 27:
20Oral Communications: Molecular He
- Page 28 and 29:
22Oral Communications: Molecular He
- Page 30 and 31:
24Oral Communications: Hematopoieti
- Page 32 and 33:
26Oral Communications: Hematopoieti
- Page 34 and 35:
28Oral Communications: Hematopoieti
- Page 36 and 37:
30Oral Communications: Non-malignan
- Page 38 and 39:
32Oral Communicationsmodulation of
- Page 40 and 41:
34Oral Communicationsfollow-up samp
- Page 42 and 43:
36Oral Communicationsinary results
- Page 44 and 45:
38Oral Communicationslow-grade NHL)
- Page 46 and 47: 40Oral CommunicationsOral Communica
- Page 48 and 49: 42Oral Communicationsboth increased
- Page 50 and 51: 44Oral CommunicationsCO-40POTENTIAL
- Page 52 and 53: 46Oral Communicationsshowed an exte
- Page 54 and 55: 48Oral CommunicationsThe molecular
- Page 56 and 57: 50Oral Communicationsthe transcript
- Page 58 and 59: 52Oral Communicationsing to apoptot
- Page 60 and 61: 54Oral CommunicationsCO-54NEOPLASTI
- Page 62 and 63: 56Oral CommunicationsOral Communica
- Page 64 and 65: 58Oral Communicationssystem-Promega
- Page 66 and 67: 60Oral Communicationsthe relationsh
- Page 68 and 69: 62PostersPosterACUTE MYELOID LEUKEM
- Page 70 and 71: 64Postersone course of CI-FLA. Ther
- Page 72 and 73: 66Postersed to GST deletions and CY
- Page 74 and 75: 68Posterstion until optimal VPA pla
- Page 76 and 77: 70Posterseffective biotechnological
- Page 78 and 79: 72Postersdirectly to maintenance th
- Page 80 and 81: 74PostersPosterACUTE LYMPHOID LEUKE
- Page 82 and 83: 76Postersformed in half the patient
- Page 84 and 85: 78Posterspatients correlating data
- Page 86 and 87: 80Postersleukemia-related and thus
- Page 88 and 89: 82PostersCD33/CD16, CD13/CD16, CD45
- Page 90 and 91: 84PostersIn myelodysplastic syndrom
- Page 92 and 93: 86Postersin our series of 376 conse
- Page 94 and 95: 88PostersPO-041FUNCTIONAL ANALYSIS
- Page 98 and 99: 92Postersof AML blasts to RA. In su
- Page 100 and 101: 94Postersafter 72-96 h treatment wi
- Page 102 and 103: 96PostersPosterMOLECULAR HEMATOLOGY
- Page 104 and 105: 98Postersanalyse the transcribed HU
- Page 106 and 107: 100Postersed with the gain of the i
- Page 108 and 109: 102Postershowever, been reported in
- Page 110 and 111: 104Postersand the intrinsic apoptot
- Page 112 and 113: 106Postersferentation by BM stromal
- Page 114 and 115: 108PostersPO-075NONMYELOABLATIVE AL
- Page 116 and 117: 110Posters9-12, 17-20/28 d on odd c
- Page 118 and 119: 112PostersPosterMULTIPLE MYELOMA II
- Page 120 and 121: 114Posterssion, the immunomodulator
- Page 122 and 123: 116Posters(p-ERK1/2) levels in myel
- Page 124 and 125: 118PostersPO-092ROLE OF THE MEVALON
- Page 126 and 127: 120Postershis study evaluates the p
- Page 128 and 129: 122PostersPosterNON-ONCOLOGICAL HEM
- Page 130 and 131: 124PostersPO-101A WHOLE BLOOD FLOW
- Page 132 and 133: 126Postersthat ITP DCs, after pulsi
- Page 134 and 135: 128PostersTherefore in the proposit
- Page 136 and 137: 130Postersods and early effective a
- Page 138 and 139: 132PostersPO-116FIP1L1-PDGFRA FUSIO
- Page 140 and 141: 134Postersand of course, as reducti
- Page 142 and 143: 136Posterscurrently under study bec
- Page 144 and 145: 138Postersmg/day (Haematologica 200
- Page 146 and 147:
140Postersno severe reaction were o
- Page 148 and 149:
142PostersCML for clinical and haem
- Page 150 and 151:
144PostersPO-135THE ATG-SAPORIN-S6
- Page 152 and 153:
146Postersthrough a flow cytometry-
- Page 154 and 155:
148Posterspredominant TCR peak prec
- Page 156 and 157:
150Postersrejection or cytopenia, w
- Page 158 and 159:
152Postersphocytes. Anti-leptin blo
- Page 160 and 161:
154Postersmy), which the patient re
- Page 162 and 163:
156Postersgr/m 2 +GCSF) followed by
- Page 164 and 165:
158Postersremission of 100% of MCL
- Page 166 and 167:
160Posterswould require an early an
- Page 168 and 169:
162PostersPO-165SPONTANEOUS MOBILIZ
- Page 170 and 171:
164PostersPO-168TLR7 AND TLR9 LIGAN
- Page 172 and 173:
166PostersFR and/or CDR clustering
- Page 174 and 175:
168PostersPO-174INDUCTION OF FAS UP
- Page 176 and 177:
170Postersup data were available, m
- Page 178 and 179:
172Posterssamples showing RFC methy
- Page 180 and 181:
174PostersIn the last few years the
- Page 182 and 183:
176PostersPO-187RELAPSED/REFRACTORY
- Page 184 and 185:
178Posters1.The association of prim
- Page 186 and 187:
180Posterswith generalizated lympho
- Page 188 and 189:
182PostersPO-196EPRATUZUMAB/SAPORIN
- Page 190 and 191:
184Postersantioxidant capacity of p
- Page 192 and 193:
186PostersCD16/CD56 + (NK) cells an
- Page 194 and 195:
188Postersby PBSCT, as the general
- Page 196 and 197:
190Postersnode biopsies, three from
- Page 198 and 199:
192PostersPO-212ANALYSIS OF IGV GEN
- Page 200 and 201:
194Postershaematologica vol. 89[sup
- Page 202 and 203:
IIVIII Congress of the Italian Soci
- Page 204 and 205:
IVVIII Congress of the Italian Soci
- Page 206 and 207:
VIVIII Congress of the Italian Soci
- Page 208 and 209:
VIIIVIII Congress of the Italian So
- Page 210 and 211:
XVIII Congress of the Italian Socie